“…Specific subtypes of breast cancer such as estrogen receptor (ER)-negative, human EGF receptor 2 (HER2)-positive, and triple-negative breast cancer (TNBC) have shown evidence of immunogenicity based on tumor–immune interactions. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso

“…To assess for clonal replacement, we devise a summary statistic based on whole-exome sequencing of a pre-treatment biopsy and multi-region sampling of the post-treatment surgical specimen and apply this measure to five breast tumors treated with neoadjuvant HER2-targeted therapy. Two tumors underwent clonal replacement with treatment, and mathematical modeling indicates these two tumors had resistant subclones prior to treatment and rates of resistance-related genomic changes that were substantially larger than previous estimates. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: EGFR and HER2 overexpression has been reported to play important roles in colorectal cancer (CRC) development and metastasis. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Phosphorylation of HER3 by its canonical dimerization partners, EGFR and HER2, is achieved by engaging an allosteric site on the HER3 kinase domain, but this site is not required when HER3 is phosphorylated by MET. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Since the discovery of the human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers and the development of HER2 directed therapies, the prognosis of HER2 amplified breast cancers has improved meaningfully. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: The ERBB2 oncogene hypothesis is challenged in hepatocellular carcinoma (HCC) with the conflicting evidences of human epidermal growth factor receptor 2 (HER2) overexpression. HER2 could be a new target as a treatment option for HCC as well as tumor recurrence after surgery. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: HER2 is the only validated predictive biomarker in gastro-oesophageal carcinoma (GOC). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…HER2 2+ status was confirmed by fluorescence in situ hybridization. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The key difference between SumHer and the existing software LD Score Regression (LDSC) is that SumHer allows the user to specify the heritability model. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The promising compounds were evaluated for their inhibitory profile against epidermal growth factor (EGFR) and HER2 enzymes. Compound 10 showed more potent activity on both EGFR and HER2 than erlotinib (IC(50) 3.90 and 5.40 µM versus 6.21 and 9.42 µM). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…A study was performed to evaluate the rate of HER2 positivity in patients with primary gastric cancer and to assess the relationship between HER2-positive and Borrmann classification. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We applied thickness shear mode acoustics method (TSM) for detection of SK-BR-3 breast cancer cells using DNA aptamers specific to HER2 positive membrane receptors. The biotinylated aptamers were immobilized at the neutravidin layer chemisorbed at gold surface of TSM transducer. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Here, we describe the synthesis of spherical gold nanoparticles surface-functionalized with an anti-HER2 antibody-drug conjugate (ADC) as an active targeting agent that carries a cytotoxic payload. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Disease outcomes of HER2+ breast cancers have dramatically improved after targeted therapies, such as trastuzumab became available. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Background: HER2 (human epidermal growth factor 2)-positive breast cancer is an aggressive type of breast cancer characterized by the overexpression of the receptor-type protein tyrosine kinase HER2 or amplification of the HER2 gene. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Although breast cancer is a heterogeneous disease, approximately 20% to 25% of patients diagnosed with breast cancer have amplification of the HER2 gene. The FDA approval of trastuzumab for the treatment of HER2-positive (HER2+) metastatic breast cancer in 1998 represented a major breakthrough for patients with HER2+ disease. …”
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso

“…However, the role of PD-L1 expression in HER2-positive breast cancer remains unclear. We investigated the clinicopathological utility of PD-L1 expression in HER2-positive breast cancer. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso